177 related articles for article (PubMed ID: 32514049)
1. Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Roberts TA; Hyare H; Agliardi G; Hipwell B; d'Esposito A; Ianus A; Breen-Norris JO; Ramasawmy R; Taylor V; Atkinson D; Punwani S; Lythgoe MF; Siow B; Brandner S; Rees J; Panagiotaki E; Alexander DC; Walker-Samuel S
Sci Rep; 2020 Jun; 10(1):9223. PubMed ID: 32514049
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive assessment of glioma microstructure using VERDICT MRI: correlation with histology.
Zaccagna F; Riemer F; Priest AN; McLean MA; Allinson K; Grist JT; Dragos C; Matys T; Gillard JH; Watts C; Price SJ; Graves MJ; Gallagher FA
Eur Radiol; 2019 Oct; 29(10):5559-5566. PubMed ID: 30888488
[TBL] [Abstract][Full Text] [Related]
3. Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for cytometry in tumours magnetic resonance imaging.
Panagiotaki E; Chan RW; Dikaios N; Ahmed HU; O'Callaghan J; Freeman A; Atkinson D; Punwani S; Hawkes DJ; Alexander DC
Invest Radiol; 2015 Apr; 50(4):218-27. PubMed ID: 25426656
[TBL] [Abstract][Full Text] [Related]
4. Radiomics Analysis for Glioma Malignancy Evaluation Using Diffusion Kurtosis and Tensor Imaging.
Takahashi S; Takahashi W; Tanaka S; Haga A; Nakamoto T; Suzuki Y; Mukasa A; Takayanagi S; Kitagawa Y; Hana T; Nejo T; Nomura M; Nakagawa K; Saito N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):784-791. PubMed ID: 31344432
[TBL] [Abstract][Full Text] [Related]
5. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
6. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
[TBL] [Abstract][Full Text] [Related]
7. Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.
Porcari P; Hegi ME; Lei H; Hamou MF; Vassallo I; Capuani S; Gruetter R; Mlynarik V
NMR Biomed; 2016 Nov; 29(11):1577-1589. PubMed ID: 27717037
[TBL] [Abstract][Full Text] [Related]
8. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
9. Pulsed and oscillating gradient MRI for assessment of cell size and extracellular space (POMACE) in mouse gliomas.
Reynaud O; Winters KV; Hoang DM; Wadghiri YZ; Novikov DS; Kim SG
NMR Biomed; 2016 Oct; 29(10):1350-63. PubMed ID: 27448059
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Brain Tumour Characterisation with VERDICT-MRI: Evaluation of Cellular and Vascular Measures Validated by Histology.
Figini M; Castellano A; Bailo M; Callea M; Cadioli M; Bouyagoub S; Palombo M; Pieri V; Mortini P; Falini A; Alexander DC; Cercignani M; Panagiotaki E
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173965
[TBL] [Abstract][Full Text] [Related]
11. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Wu S; Calero-Pérez P; Arús C; Candiota AP
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
[TBL] [Abstract][Full Text] [Related]
13. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
14. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine.
Derlon JM; Petit-Taboué MC; Chapon F; Beaudouin V; Noël MH; Creveuil C; Courtheoux P; Houtteville JP
Neurosurgery; 1997 Feb; 40(2):276-87; discussion 287-8. PubMed ID: 9007859
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
[TBL] [Abstract][Full Text] [Related]
16. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.
Bader JB; Samnick S; Moringlane JR; Feiden W; Schaefer A; Kremp S; Kirsch CM
Eur J Nucl Med; 1999 Feb; 26(2):144-51. PubMed ID: 9933348
[TBL] [Abstract][Full Text] [Related]
18. ADC texture--an imaging biomarker for high-grade glioma?
Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
20. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
